Suchergebnisse - "Fox, Robert J"

PubPharm (347)

1

Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis

enthalten in: Neurology | 2024

von Fox, R. | Cree, B. | de Sèze, J. | +18

2

Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis : Extended Results of a Placebo-Controlled Phase 2 Trial

enthalten in: Neurology(R) neuroimmunology & neuroinflammation | 2024

von Fox, R. | Wiendl, H. | Wolf, C. | +12

3

Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2024

von Nakamura, K. | Thoomukuntla, B. | Bena, J. | +3

4

Clinical trials for progressive multiple sclerosis : progress, new lessons learned, and remaining challenges

enthalten in: The Lancet. Neurology | 2024

von Chataway, J. | Williams, T. | Li, V. | +3

5

Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2024

von Ladakis, D. | Reyes-Mantilla, M. | Gadani, S. | +8

6

Pathophysiology, Diagnosis, Treatment and Emerging Neurotherapeutic Targets for Progressive Multiple Sclerosis : The Age of PIRA

enthalten in: Neurologic clinics | 2024

von Carlson, A. | Fox, R.

7

Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2023

von Nakamura, K. | Zheng, Y. | Mahajan, K. | +3

8

Assisted ambulation to improve health outcomes for older medical inpatients (AMBULATE) : study protocol for a randomized controlled trial

enthalten in: Trials | 2023

von Johnson, J. | Hamilton, A. | Hu, B. | +10

9

Assisted ambulation to improve health outcomes for older medical inpatients (AMBULATE): study protocol for a randomized controlled trial

enthalten in: Trials | 2023

von Johnson, J. | Hamilton, A. | Hu, B. | +10

10

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS) : a multicentre, randomised, single-blind, phase 4, non-inferiority trial

enthalten in: The Lancet. Neurology | 2023

von Corboy, J. | Fox, R. | Kister, I. | +25

CommentIn: Lancet Neurol. 2023 Jul;22(7):543-545. - PMID 37353269

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[35]